SAB Biotherapeutics Warrant
SABSW
7 hedge funds and large institutions have $28.1K invested in SAB Biotherapeutics Warrant in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0.19% less ownership
Funds ownership: 9.53% → 9.34% (-0.19%)
22% less funds holding
Funds holding: 9 → 7 (-2)
58% less capital invested
Capital invested by funds: $66.3K → $28.1K (-$38.2K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
+$559 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
-$810 |
| 2 |
Walleye Trading
New York
|
-$386 |
| 3 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$226 |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$122 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $18.8K | – | – | – |
|
2
Morgan Stanley
New York
| $3.81K | – | – | – |
|
|
YCM
3
Yakira Capital Management
Westport,
Connecticut
| $2.35K | -$810 | -14,497 | -16% |
|
|
HWM
4
HB Wealth Management
Atlanta,
Georgia
| $2.09K | +$559 | +9,999 | +20% |
|
|
5
Walleye Trading
New York
| $828 | -$386 | -6,900 | -18% |
|
|
WAM
6
Wolverine Asset Management
Chicago,
Illinois
| $161 | -$226 | -4,035 | -47% |
|
|
NA
7
NewEdge Advisors
New Orleans,
Louisiana
| $28 | – | – | – |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$122 | -1,633 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$4 | -48 | Closed |
|
SABSW Hedge Fund Activity: Q1 2025 in Review
7 of the 7,461 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q1 2025, worth a combined $28.1K — down 58% from $66.3K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of SABSW and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was HB Wealth Management, adding an estimated $559. The largest seller was Yakira Capital Management, cutting an estimated $810.
- 7 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q1 2025, down from 9 in Q4 2024.
- Funds reported $28.1K of SAB Biotherapeutics Warrant stock for Q1 2025, down 58% quarter-over-quarter.
- 0 funds opened new SAB Biotherapeutics Warrant positions in Q1 2025 and 2 closed out, a net change of -2 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q1 2025 was HB Wealth Management, an estimated $559 added.
- The largest SAB Biotherapeutics Warrant seller in Q1 2025 was Yakira Capital Management, an estimated $810 sold.
Based on aggregated 13F filings for Q1 2025.